Status:
TERMINATED
Subjective Sleep Quality and Sleep Disorders in Patients With Severe Asthma
Lead Sponsor:
Istituti Clinici Scientifici Maugeri SpA
Conditions:
Asthma
Eligibility:
All Genders
18+ years
Brief Summary
Bronchial asthma is characterized by the presence of symptoms that vary over time and of severity. Asthma symptoms tend to worsen at night and in the early hours of the morning, and the presence of no...
Detailed Description
Rationale Bronchial asthma is a heterogeneous and highly prevalent disease; moreover, it represents one of the main cost of the Italian National Health Care System. According to international guideli...
Eligibility Criteria
Inclusion
- Diagnosis of severe persistent asthma
- Systemic steroids treatment for at least 6 months and/or ≥2 exacerbations in the last year
- Need to initiate monoclonal antibody therapy according to guidelines
- Age ≥18 years
- Signed Informed consent
- Patients able to collaborate in the required procedures
Exclusion
- Diagnosis of cognitive impairment
Key Trial Info
Start Date :
September 10 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 5 2023
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT04340583
Start Date
September 10 2019
End Date
June 5 2023
Last Update
July 6 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Istituti Clinici Maugeri Pneumologia
Tradate, Lombardy, Italy, 21049